Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The polymorphic enzyme CYP2C19 is of importance for the metabolism and effects of omeprazole during short‐term treatment. Aim: To investigate the relationship between CYP2C19 genotype and the effects of long‐term omeprazole treatment. Material and methods: A total of 180 patients with acid related disorders were genotyped for wild type and mutated CYP2C19 alleles by allele‐specific PCR amplification. Gastrin and chromogranin A were assessed by radioimmunoassays, and pepsinogen I and H. pylori serology were assessed by ELISA methods. Results: In 108 of the patients, who received a single dose of 20 mg omeprazole, there was no difference in gastrin and chromogranin A concentrations between the three CYP2C19 genotypes. In 72 patients on long‐term treatment (> 1 year) with 20 mg omeprazole daily, serum gastrin as well as plasma chromogranin A concentrations (mean ± s.e.) were both about threefold higher in the wild type/mutated (52.1 ± 7.6 p M and 7.3 ± 1.3 n M (n=19), respectively) compared to wild type/wild type (14.7 ± 0.9 p M and 2.5 ± 0.1 n M (n=52), respectively; both comparisons P=0.0001). In a single mutated/mutated patient on long‐term treatment, both gastrin and chromogranin A were high (88 p M and 13.7 n M, respectively). Serum pepsinogen I concentration was significantly lower in wild type/mutated (n=19) patients on long‐term treatment, compared with the corresponding wild type/wild type (n=49) group (147 ± 19 μg/L vs. 193 ± 12 μg/L, P=0.04). Conclusion: Patients with one (and probably also with two) mutated CYP2C19 allele(s) on long‐term treatment with omeprazole had significantly affected serum gastrin and pepsinogen I and plasma chromogranin A concentrations compared with patients with two normal alleles. This indicates that changes in gastric mucosal morphology during omeprazole treatment might be dependent upon the degree of the individual’s capacity to metabolize omeprazole.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum, H. L., Arnestad, J. S., Brenna, E., Eide, I., Syversen, U., & Sandvik, A. K. (1996) · Gut · doi:10.1136/gut.39.5.649 · Cited by 243
Cited by
Pathogenesis of Helicobacter pylori Infection
Kusters, J. G., van Vliet, A. H. M., & Kuipers, E. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00054-05 · Cited by 2,526
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A., & Ishizaki, T. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.153 · Cited by 257
Giusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500299 · Cited by 111
Metadata
- Authors
- Sagar, M., Bertilsson, L., Stridsberg, M., Kjellin, A., Mårdh, S., & Seensalu, R.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-11-27
- Volume
- 14
- Issue
- 11
- Pages
- 1495-1502
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2081846604
- Cited by
- 38
- References
- 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00835.x
- The paper
- Sagar, M., Bertilsson, L., Stridsberg, M., Kjellin, A., Mårdh, S., & Seensalu, R. (2000). Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00835.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.